Kangmei Pharma | 600518 - Interest Expense On Debt


Kangmei Pharma reported CNY1.82M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Akebia Therapeutics 362.52M 357.69M Mar/2026
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Avita Medical AUD 1.25M 100K Jun/2025
Cspc Pharmaceutical CNY 6.76M 3.43M Dec/2025
Dianthus Therapeutics USD 4.44M 263K Sep/2024
Genomma Lab Internacional MXN 190.68M 972K Dec/2025
Hypermarcas BRL 36.54M 3.75M Dec/2025
Ionis Pharmaceuticals USD 17M 1000K Mar/2026
IQVIA Holdings USD 192M 1000K Mar/2026
Jiangsu Hengrui CNY 254.59M 253.85M Sep/2025
Kangmei Pharma CNY 1.82M 150K Sep/2025
Moderna USD 11.49B 36B Mar/2026
Organon & Co USD 128M 3M Sep/2025
Revvity USD 24.72M 1.2M Mar/2026
Sh Fosun Pharma CNY 321.25M 2M Sep/2025
Tectonic Therapeutic USD 246.58M 246.56M Mar/2026
Viatris USD 120.1M 500K Mar/2026
Wuxi Apptec CNY 103.05M 37.29M Jun/2025
Xeris Pharmaceuticals USD 7.15M 115K Dec/2025
Zz Pientze Pharmaceu CNY 46.05M 36.5M Jun/2025